Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
fda.gov U.S
GLP-1 drugs could treat more than just diabetes and obesity
When branded therapies of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) commanded high prices and faced prolonged shortages from late 2022 through early 2025, compounding pharmacies emerged as alternative providers offering lower-cost formulations
Whether you start at a low microdose or escalate to a higher maintenance dose, you pay the same monthly rate with no per-dose surcharges
Cummings DE, Clement K, Purnell JQ, et al
Metformin also carries a low risk of weight gain and is considered a neutral player in metabolic health, which is why it remains a first-line medication for metabolic conditions
US$ 27.30
US$ 22.74
US$ 22.93
US$ 24.68
US$ 27.20
